热门资讯> 正文
Artiva Biotherapeutics Reports Wider Q2 Loss, No Revenue
2024-08-30 05:31
05:31 PM EDT, 08/29/2024 (MT Newswires) -- Artiva Biotherapeutics (ARTV) reported a Q2 loss late Thursday of $22 per diluted share, wider than a loss of $14.09 a year earlier.
Four analysts surveyed by Capital IQ expected a loss of $4.40.
No revenue for the quarter ended June 30 was reported. Revenue a year earlier was $3.5 million.
Four analysts polled by Capital IQ estimated $80,000.
As of June 30, the company said it had $46.6 million in cash, cash equivalents, and short-term investments. It said the $179 million in gross proceeds from its initial public offering in July extends cash runway at least through the end of 2026 and through key clinical data milestones.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
